A new epinephrine nasal spray has been approved by the Food and Drug Administration (FDA) for the treatment of allergic reactions, including anaphylaxis, in adult and pediatric patients who weight at least 66 pounds, according to an FDA press release. Until now, epinephrine has only been available for patients as an injection or auto-injection device. The agency says the new delivery mechanism addresses an unmet need in that some people who need urgent epinephrine treatment may delay or avoid it because of fear of injections. Epinephrine is the only life-saving treatment for anaphylaxis related to common allergens such as certain foods, medications, and insect stings, the agency says. The product—known as “Neffy”—is a 2 mg single dose nasal spray administered into 1 nostril. A second dose in the same nostril may be administered if there is no initial improvement in symptoms or symptoms worsen.
Great need for treatment: According to manufacturer ARS Pharmaceuticals, only 3 million people have a current prescription for epinephrine, while about 40 million have Type I severe allergic reactions and should have access to epinephrine. A Neffy site for healthcare professionals includes indications and contraindications.
Read More
- Anaphylaxis: Clinical Guidelines for Diagnosis and Management
- Most Kids in Anaphylaxis Have No Treatment Before Presenting to Urgent Care or ED